We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Mirum Pharmaceuticals Inc
4 own
3 watching
Current Price
$26.93
$0.6
(2.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,023.67M
52-Week High
30.545
52-Week Low
17.315
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,023.67M52-Week High30.54552-Week Low17.315Average Volume0.21MDividend Yield--P/E Ratio--What does the Mirum Pharmaceuticals Inc do?
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Read More
How much money does Mirum Pharmaceuticals Inc make?
News & Events about Mirum Pharmaceuticals Inc.
Business Wire
1month ago
Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act...
Business Wire
1month ago
Mirum Pharmaceuticals, Inc. (Mirum) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the notes) in a private offering to qualified institutional buyers pursuant to Rule 144A...
Business Wire
1month ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023. The companys preliminary unaudited financial results for the first quarter of 2023 include: Approximately $31.5 million of total revenue...
Business Wire
1month ago
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on April 10, 2023, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 25,950 shares of common stock and 12,960 restricted stock units (RSUs) to five...
Benzinga
2 months ago
Latest Ratings for MIRM
DateFirmActionFromTo Mar 2022Raymond JamesMaintainsStrong Buy Jan 2022SVB LeerinkMaintainsOutperform Jan 2022Raymond JamesMaintainsStrong Buy
View More Analyst Ratings for MIRM
View the Latest Analyst Ratings
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Mirum Pharmaceuticals Inc share price today?
Can Indians buy Mirum Pharmaceuticals Inc shares?
How can I buy Mirum Pharmaceuticals Inc shares from India?
Can Fractional shares of Mirum Pharmaceuticals Inc be purchased?
What are the documents required to start investing in Mirum Pharmaceuticals Inc stocks?
What is today’s traded volume of Mirum Pharmaceuticals Inc?
What is today’s market capitalisation of Mirum Pharmaceuticals Inc?
What is the 52-Week High and Low Range of Mirum Pharmaceuticals Inc?
What percentage is Mirum Pharmaceuticals Inc down from its 52-Week High?
What percentage is Mirum Pharmaceuticals Inc up from its 52-Week Low?
Current Price
$26.93
$0.6
(2.28%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.